Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Rite Aid Stock Down 80% This Year: Is Amazon The Only Threat?

By Zacks Investment ResearchStock MarketsOct 12, 2017 10:09PM ET
www.investing.com/analysis/rite-aid-stock-down-80-this-year-is-amazon-the-only-threat-200218677
Rite Aid Stock Down 80% This Year: Is Amazon The Only Threat?
By Zacks Investment Research   |  Oct 12, 2017 10:09PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

A lot has been going on with drugstore chain retailer Rite Aid Corporation (NYSE:RAD) , which has lost a whopping 80% this year, much wider than the industry’s decline of 12.5%. In fact, the stock has plunged nearly 21% over the past week, on speculations of Amazon.com Inc.’s (NASDAQ:AMZN) entry in the drugstore business.





After Amazon’s takeover of Whole Foods Market (NASDAQ:WFM) — a move that has kept grocery retailers on their toes — it looks like the online giant is now eyeing the drugstore industry. Though the news hasn’t been confirmed by Amazon, various media reports suggest that the e-commerce king is undertaking several steps to enter the prescription drug distribution space. Per the reports, Amazon is in talks with pharmacy benefit managers and various talented personnel to analyze the drugstore trends to foray into the market.

However, Amazon’s expansion strategy is just one of the reasons behind Rite Aid’s debacle. Let’s take a look at the other reasons for which this Zacks Rank #4 (Sell) stock has lost ground.

Merger Fallout With Walgreens

Rite Aid suffered a huge setback in June, when its merger with Walgreens Boots Alliance Inc. (NASDAQ:WBA) was terminated for failing to get the Federal Trade Commission’s (FTC) nod after two years of investigation. Thereafter, Walgreens agreed upon a fresh bargain to buy 2,186 Rite Aid stores, associated distribution assets and inventory, for $5.175 billion as well as termination charges of $325 million. However, this contract was also amended recently, to Walgreens agreeing to buy 1,932 Rite Aid stores, three distribution centers and related inventory in an all-cash deal. The former will now pay $4.375 billion for the deal. While this proposal finally won the FTC’s clearance last month, the string of all these events weighed upon investors’ sentiment.

Unfavorable Reimbursement Rates Dent Margins

Rite Aid has been battling unfavorable reimbursement rates for a while now. Evidently, lower pharmacy reimbursement rates dented the company’s Retail Pharmacy gross profit, which in turn hurt Rite Aid’s adjusted EBITDA in the first two quarters of fiscal 2018. Well, Rite Aid’s adjusted EBITDA margin contracted 100 and 110 bps in the first and second quarters of fiscal 2018, respectively. Nevertheless, termination charges of $325 million received from Walgreens partly cushioned Rite Aid’s operating results in the second quarter. However, management expects reimbursement rates to continue to pressurize pharmacy margins in the second half of the fiscal.

Unimpressive Surprise History, Dismal Q2 Performance

Rite Aid’s earnings surprise history is not very impressive. The company has underperformed the Zacks Consensus Estimate by an average of 20.8% in the trailing four quarters, including two quarters of negative earnings surprise. Though the company’s bottom-line matched the Zacks consensus mark in the second quarter of fiscal 2017, the company reported a loss of 1 cent as against the year-ago period earnings of 3 cents per share. Additionally, the top line remained soft, with same store sales declining on account of lower pharmacy and front-end sales. Apart from these factors, Rite Aid’s second-quarter debacle could be attributable to the impact of the merger ditch as well as the reduced reimbursement rates, as discussed above.

Any Positive Signals Ahead?

While the final pact with Walgreens will reduce Rite Aid’s core business, it is likely to lower Rite Aid’s debt position and improve its financial leverage and balance sheet. Management stated that it intends to use the funds from this deal to repay roughly $270 million worth of net liabilities associated with the divested assets; nearly $100 million of restructuring expenses and transaction fees and $85 million as income tax. Moreover, Rite Aid will continue to operate its pharmacy benefit manager — EnvisionRX, RediClinic and Health Dialog.

Thus, the latest contract should make Rite Aid a smaller, but stronger firm with lesser exposure to the pressures of unfavorable pharmacy reimbursement rates. However, management chose not to provide any guidance until it gets any clarity on the timing of its planned store divestitures. So for now, we prefer to remain on the sidelines.

Still Want Exposure in the Drugstore Segment?

Investors can count on Diplomat Pharmacy, Inc. (NYSE:DPLO) , which has delivered back-to-back positive earnings surprises in the past two quarters, and carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

4 Stocks to Watch after the Massive Equifax (NYSE:EFX) Hack

Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?

Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.

Get the new Investing Guide now>>



Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Rite Aid Corporation (RAD): Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report

Diplomat Pharmacy, Inc. (DPLO): Free Stock Analysis Report

Original post

Zacks Investment Research
Rite Aid Stock Down 80% This Year: Is Amazon The Only Threat?
 

Related Articles

Rite Aid Stock Down 80% This Year: Is Amazon The Only Threat?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email